SYNDAX PHARMACEUTICALS INC (SNDX) Stock Price, Quote, News and Overview
NASDAQ:SNDX - Nasdaq - US87164F1057 - Common Stock - Currency: USD
SNDX Quote, Performance and Key Statistics
10.81
+0.16 (+1.5%)
The current stock price of SNDX is 10.81 USD. In the past month the price decreased by -18.72%. In the past year, price decreased by -46.7%.
SNDX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 17.77 | 322.91B | ||
| AMGN | AMGEN INC | 13.1 | 146.19B | ||
| GILD | GILEAD SCIENCES INC | 13.79 | 132.89B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | N/A | 111.58B | ||
| REGN | REGENERON PHARMACEUTICALS | 13.47 | 64.44B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 37.59B | ||
| ARGX | ARGENX SE - ADR | 99.05 | 35.50B | ||
| ONC | BEIGENE LTD-ADR | 5.93 | 25.74B | ||
| BNTX | BIONTECH SE-ADR | N/A | 23.82B | ||
| NTRA | NATERA INC | N/A | 20.73B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 19.14B | ||
| BIIB | BIOGEN INC | 7.98 | 18.51B |
Related stock screener links
About SNDX
Company Profile
Syndax Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company engaged in the development of cancer therapies. The company is headquartered in New York City, New York and currently employs 270 full-time employees. The company went IPO on 2016-03-03. The company is focused on developing pipeline of cancer therapies. Its product candidates include revumenib, and axatilimab. The company is developing revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged also known as mixed lineage leukemia rearranged, acute leukemias including acute lymphoblastic leukemia and acute myeloid leukemia (AML), and necleophosmin 1, also known as NPM1, mutant A. The company is also exploring the use of revumenib as a treatment in solid tumors, specifically its activity in metastatic colorectal cancer. The company is also developing axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1 receptor (CSF-1R) in chronic graft-versus-host disease (cGVHD), as well as idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells.
Company Info
SYNDAX PHARMACEUTICALS INC
730 Third Avenue, 9Th Floor
New York City NEW YORK 02451 US
CEO: Briggs W. Morrison
Employees: 270
Phone: 17814191400
SYNDAX PHARMACEUTICALS INC / SNDX FAQ
What is the stock price of SYNDAX PHARMACEUTICALS INC today?
The current stock price of SNDX is 10.81 USD. The price increased by 1.5% in the last trading session.
What is the ticker symbol for SYNDAX PHARMACEUTICALS INC stock?
The exchange symbol of SYNDAX PHARMACEUTICALS INC is SNDX and it is listed on the Nasdaq exchange.
On which exchange is SNDX stock listed?
SNDX stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for SYNDAX PHARMACEUTICALS INC stock?
19 analysts have analysed SNDX and the average price target is 35.51 USD. This implies a price increase of 228.53% is expected in the next year compared to the current price of 10.81. Check the SYNDAX PHARMACEUTICALS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is SYNDAX PHARMACEUTICALS INC worth?
SYNDAX PHARMACEUTICALS INC (SNDX) has a market capitalization of 930.09M USD. This makes SNDX a Small Cap stock.
How many employees does SYNDAX PHARMACEUTICALS INC have?
SYNDAX PHARMACEUTICALS INC (SNDX) currently has 270 employees.
What are the support and resistance levels for SYNDAX PHARMACEUTICALS INC (SNDX) stock?
SYNDAX PHARMACEUTICALS INC (SNDX) has a resistance level at 10.82. Check the full technical report for a detailed analysis of SNDX support and resistance levels.
Is SYNDAX PHARMACEUTICALS INC (SNDX) expected to grow?
The Revenue of SYNDAX PHARMACEUTICALS INC (SNDX) is expected to grow by 4.29% in the next year. Check the estimates tab for more information on the SNDX EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy SYNDAX PHARMACEUTICALS INC (SNDX) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of SNDX, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of SNDX, evaluating the profitability, health, valuation and growth aspects
- SYNDAX PHARMACEUTICALS INC (SNDX) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- SYNDAX PHARMACEUTICALS INC (SNDX) Sales and EPS estimates to see what analysts future expectations are.
- SYNDAX PHARMACEUTICALS INC (SNDX) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- SYNDAX PHARMACEUTICALS INC (SNDX) Insider and Institutional Ownership to learn about the owners and their transactions.
- SYNDAX PHARMACEUTICALS INC (SNDX) Stock Chart to make your own analysis
- SYNDAX PHARMACEUTICALS INC (SNDX) Latest news and press-releases to stay up to date.
Does SYNDAX PHARMACEUTICALS INC (SNDX) stock pay dividends?
SNDX does not pay a dividend.
When does SYNDAX PHARMACEUTICALS INC (SNDX) report earnings?
SYNDAX PHARMACEUTICALS INC (SNDX) will report earnings on 2025-07-30.
What is the Price/Earnings (PE) ratio of SYNDAX PHARMACEUTICALS INC (SNDX)?
SYNDAX PHARMACEUTICALS INC (SNDX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.86).
What is the Short Interest ratio of SYNDAX PHARMACEUTICALS INC (SNDX) stock?
The outstanding short interest for SYNDAX PHARMACEUTICALS INC (SNDX) is 25.49% of its float. Check the ownership tab for more information on the SNDX short interest.
SNDX Technical Analysis
SNDX Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to SNDX. SNDX may be in some trouble as it scores bad on both profitability and health.
SNDX Financial Highlights
Over the last trailing twelve months SNDX reported a non-GAAP Earnings per Share(EPS) of -3.86. The EPS decreased by -19.88% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -51.69% | ||
| ROE | -154.01% | ||
| Debt/Equity | 1.54 |
SNDX Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 85% to SNDX. The Buy consensus is the average rating of analysts ratings from 19 analysts.
For the next year, analysts expect an EPS growth of -0.52% and a revenue growth 4.29% for SNDX